A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

I1F-MC-RHBS -

The main purpose of this study is to evaluate the efficacy of the study drug ixekizumab compared to ustekinumab in participants with moderate-to-severe-plaque psoriasis.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Plaque Psoriasis
What the trial is testing?
Ixekizumab, Ustekinumab
Could I receive a Placebo?
Yes
Enrollment Goal
302
Trial Dates
Oct 1, 2015 - Oct 1, 2017
How long will I be in the trial?
Your participation could last up to 52 weeks plus a minimum of 12 weeks for post treatment follow up visits and include 18 required visits to the study center
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.